|
June 28, 2023
|
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
|
|
June 26, 2023
|
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
|
|
June 14, 2023
|
Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules
|
|
June 13, 2023
|
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
June 8, 2023
|
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
|
|
May 15, 2023
|
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
|
|
May 8, 2023
|
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
|
|
May 1, 2023
|
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
|
|
April 20, 2023
|
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
|
|
March 30, 2023
|
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
|
